Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

University of Maryland, Baltimore: Clinical Trials & FDA Approval Profile

University of Maryland, Baltimore (Global / Institutional) sponsors 67 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 37 active protocols (22 recruiting now), 11 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)26.9%
Median Closed Enrollment vs National (145 pts)15 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for University of Maryland, Baltimore
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)67
Active Pipeline (Recruiting Now)37 (22)
Completed vs Stopped Early11 / 18 (26.9%)
Median Closed Actual Enrollment15 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With University of Maryland, Baltimore
Hospital Research SiteLocationShared Protocols
University of Maryland Medical CenterBaltimore, MD10
University of MarylandBaltimore, MD6
University of Maryland/Greenebaum Cancer CenterBaltimore, MD5

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by University of Maryland, Baltimore
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT05615844Antibiotic Cement Bead Pouch Versus Negative Pressure Wound TherapyPhase IIIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the University of Maryland, Baltimore Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI